Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI eye check could catch blood pressure damage early

NCT ID NCT07471971

Diagnosis Sponsor: I.M. Sechenov First Moscow State Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 28, 2026 · Updated 3 times

Summary

This study tested an artificial intelligence tool called RetinAIcheck to see if it can accurately detect and grade hypertensive retinopathy—eye damage caused by high blood pressure. Researchers used 729 patients' eye photos and compared the AI's results to assessments by eye doctors. The goal was to see if the AI could be a reliable, fast way to screen for this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RetinAIcheck (an AI diagnostic tool)
What this could lead to
If successful, this AI could help doctors quickly and accurately detect eye damage from high blood pressure, potentially preventing vision loss.
What could go wrong
This is a completed study, but the AI was tested only on a Russian population and may not work as well in other groups. Also, AI tools can sometimes make mistakes that human doctors would catch.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

755 people

The number who actually took part.

Started

Mar 2021

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The test sample was collected at the Cardiology Clinic of the Sechenov University Clinical Hospital № 1, at the Research Institute of Eye Diseases named after M.M. Krasnov and in the Moscow Regional Clinical Research Institute named after M.F. Vladimirsky (MONIKI).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Patients with and without a diagnosis of arterial hypertension, based on medical records Exclusion Criteria: * anophthalmia, * optic nerve atrophy, * eyeball injuries, * age-related macular degeneration, * central serous chorioretinopathy, * central serous chorioretinitis, * clouding of the optical media of the eye, which affects the quality of the image.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertensive retinopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertensive retinopathy

Contacts and locations

Locations

  • University Clinical Hospital №1, Sechenov University

    Moscow, Russia